LL-37

Natural Antibiotic

AdvancedInvestigationalUse With Caution

Administration

Subcutaneous

Also Known As

Cathelicidin antimicrobial peptide, CAMP

Find on Amazon

Overview

The only cathelicidin-derived antimicrobial peptide found in humans. It provides broad-spectrum defense against bacteria, viruses, and fungi.

Safety & Considerations

Can cause localized redness, pain, or inflammation at the injection site. High doses may provoke an excessive immune response. Limited human safety data. Should be approached carefully.

Always consult a healthcare professional. This information is for educational purposes only.

Benefits

Broad-spectrum antimicrobial activity
Breaks down bacterial biofilms
Modulates inflammation
Aids in tissue repair

How It Works

Punches holes in the lipid membranes of pathogens, leading to cell death, while signaling immune cells to sites of infection.

Common Uses

Chronic stubborn infections
Gut dysbiosis
Lyme disease co-infections

Typical Protocol

100mcg - 250mcg daily via subcutaneous injection for 4-6 weeks.

Dosing information is for research reference only.

Research Status

Investigational.

For educational purposes only. Not medical advice. Consult a healthcare professional before using any peptide or research compound.

Frequently Asked Questions About LL-37

What is LL-37 used for?

Chronic stubborn infections. Gut dysbiosis. Lyme disease co-infections.

What is the typical LL-37 protocol?

100mcg - 250mcg daily via subcutaneous injection for 4-6 weeks.

Is LL-37 safe?

Safety rating: Use With Caution. Can cause localized redness, pain, or inflammation at the injection site. High doses may provoke an excessive immune response. Limited human safety data. Should be approached carefully.

How does LL-37 work?

Punches holes in the lipid membranes of pathogens, leading to cell death, while signaling immune cells to sites of infection.

This information is for educational purposes only and should not be taken as medical advice. Always consult a qualified healthcare professional.